InsmedINSM
Recorded

Insmed Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Faisal KhurshidAnalyst

All right. Good afternoon, everyone. Thank you for joining us today in London at the Jefferies Global Healthcare Conference. My name is Faisal Khurshid. I am one of the Senior Biotech Analysts here at Jefferies. Really pleased to have with us today Will Lewis, CEO of Insmed. We have a lot of interesting stuff to get through. Will, why don't you kick it off for us?

Will LewisCEO

Well, let me just say that I appreciate the opportunity to be here and tell you that we have just completed or almost completing one of the most transformational years in the company's history with the successful launch of BRINSUPRI, which I know everyone has been tracking. That product has now cleared $1 billion and is a blockbuster officially by that standard. But we believe this is just the beginning, and I think importantly, what will drive it in the future is the opportunity to address the balance of patients we have not yet reached. We are very mildly penetrated into this market opportunity. We have said there are half a million patients in the U.S. alone, 250,000 of which have two or more exacerbations, and we put tens of thousands of patients on drugs successfully, but that means we are basically 10% penetrated.

Will LewisCEO

We have a lot further to go, and that is before we start to step into some of these additional populations which are really monstrous, like the COPD and asthma comorbid population. That is just for BRINSUPRI. ARIKAYCE, now in its eighth year of launch, still growing healthily, is about to expand to frontline. That is a sevenfold increase in addressable market. That is just our first two programs. Behind that, we have a very rich and growing pipeline and a very active BD effort. So, I think we are well poised for another breakout year in 2027.

Faisal KhurshidAnalyst

Got it. All right. Well, I am going to ask an easy question and then a hard question. Maybe for the easy one, if you were to take a step back, right, and just kind of talk to investors like a year or two ago and say, "Bronchiectasis, a disease that has never had any pharmacologic treatment, you are going to come in and do $1 billion plus in your first full calendar year," people would say, "That seems like a long shot." What do you think you have done right that has enabled that success?

Will LewisCEO

Well, I appreciate the question, and it sounds like a softball, but the truth is when we Yeah, we got the hardball coming after.

Will LewisCEO

I am sure we do. I expect no less. But look, when we did the launch of ARIKAYCE, which is a drug device inhaled liposomal encapsulated antibiotic, there is no less interesting drug to try to launch into a market, even if it is first in disease. It had a 30% dropout rate. It is a drug device combination. It is used in elderly people that need a lot of handholding, and we got that to be a top 10 launch non-oncology rare disease of all time. So, we used the learnings from that, educating the market about the disease state a year prior to launch and approval of the drug to really set the stage for the best possible uptake.

Will LewisCEO

The honest truth is, as exceptional a job as the commercial team has done, and they have done an exceptional job, the greatest strength of this opportunity is the drug itself. This drug makes people feel better in many cases. That is actively reported in social media. The physician community knows about that. That encourages uptake of the drug from this moment where we are past experimentation stage and we get into really the push part where physicians decide to give this drug as a default treatment. At places like National Jewish Health in Denver, one of the best pulmonary hospitals in the country, they are no longer looking for patients. They are looking for scheduling opportunities. They are booked out months in advance, and every patient that is brought in with bronchiectasis is offered BRINSUPRI. So, this is just the beginning.

Faisal KhurshidAnalyst

Got it. In terms of the underlying execution of the company, the launch trajectory, I think it's objective to say that things have gone quite well. The drug has reached an amazing milestone. However, it's been a pretty dramatic year for your stock and from the investment perspective. Can I just get your reflections on that?

Will LewisCEO

This is the hard question? Well, I'll just tell you, we can always do better at communication, and I think when you're going with a first-in-disease drug like we were, we're trying to give as much insight into what was going well with the drug as we possibly could, and at times, that extra detail, I think, was confusing to the marketplace. What we needed to do was sort of step back and just establish what it was going to do quarter after quarter. And every quarter this year, we've beaten and raised guidance. If you look at where we are now, we're estimating that we'll do $1.35 billion-$1.4 billion for this drug in its first full year of launch, which is extraordinary. That makes it a top 20 launch of all time in any therapeutic area.

Will LewisCEO

It is really a blockbuster, and it's on its way to being a mega blockbuster, which we define as greater than $5 billion in peak sales. We've estimated it will be at least $7 billion, and that does not include the comorbid population. It does not include ex-U.S. There's an awful lot left for us to grow here, and I think as we continue to put the quarters up, the nuance of one point of communication or another or one metric or another falls into the background and is just overwhelmed by the performance.

Faisal KhurshidAnalyst

Got it. Without getting into the specifics, obviously, like any drug launch, it's essentially a formula of three things, right? It's getting patients on drug, keeping patients on drug, and the price that you have. Can you just talk at a high level about what you have seen year to date on those three categories and what you expect through 2027?

Will LewisCEO

Sure. Getting them on drug, the last and only public guidance we provided was that we had a 90% approval rate from insurance, which is extraordinary. Best benchmarks would be in the 70s. We are way out front on that one, and that is holding up pretty well. I expect it to continue to do so. I do not think there will be a big margin structure change next year as a result of renegotiation or anything like that. Market access is really good. We get patients on drug once they are approved very rapidly with a high percentage of the time. The actual conversion of patients is extremely good with this launch. Keeping them on drug. We brought up the point of persistence at the end of the first quarter, I think it was, and it sent Wall Street in a tailspin because they were worried they did not understand what it meant.

Will LewisCEO

They were concerned that the number we were quoting was high or not attractive. What people now understand, I think, is that persistence is one of the cornerstones of strength of this launch. We are at a place now where patients are going on drug and staying on drug because they feel better on drug, and that is an extraordinary boon to the future of this launch. We are talking about- Probably the best way to put this in perspective is we had hired McKinsey to do an assessment of our launch plan before the drug was launched, and they had told us that our persistence estimate that we were targeting was crazy high.

Will LewisCEO

We are 20 percentage points above what McKinsey had said would be the appropriate benchmark, which should give you some idea of how strong that is. Then your final question, or final element, get them on drug, keep them on drug- Price and price.

Will LewisCEO

The price for this is in the $80,000 range. It is a little bit above that. Importantly, that has carried forward into international locations. We now get a price north of JPY 50,000 in Japan. Japan is launched just recently. There are 150,000 patients in Japan. Our team over there has done an exceptional job with ARIKAYCE, coming to account for almost 25% of our sales at times. As we look forward to the future of Japan, we have 200 folks over there. We are adding another 50 sales reps, which will really kick in by the middle of next year.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day